benefit

Adding Ibrance to fulvestrant does not benefit patients with breast cancer refractory to CDK4/6 inhibitors

Adding Ibrance to fulvestrant does not benefit patients with breast cancer refractory to CDK4/6 inhibitors

NEW YORK – For patients whose HER2-negative and hormone receptor-positive metastatic breast cancers progress after treatment with combination CDK4/6 inhibitors and hormone therapy, there is no additional benefit to continuing treatment with Pfizer Ibrance’s CDK4/6 inhibitor (palbociclib) plus another hormone therapy as the next line of treatment, suggest phase II study results presented at the …

Adding Ibrance to fulvestrant does not benefit patients with breast cancer refractory to CDK4/6 inhibitors Read More »

Satellites detect no real climate benefit from 10 years of California forest carbon offset

Satellites detect no real climate benefit from 10 years of California forest carbon offset

Redwood forests like this one in California can store large amounts of carbon, but not if cut down. Shane Coffield Many companies promising “net zero” emissions to protect the climate rely on large tracts of forests and so-called carbon offsets to achieve this goal. On paper, carbon offsets appear to balance a company’s carbon emissions: …

Satellites detect no real climate benefit from 10 years of California forest carbon offset Read More »